Génomique et Epidémiologie Moléculaire des Maladies Génétiques (G2MG), Centre GENOPATH, Faculté de Médecine et de Pharmacie, Mohammed V University, Rabat, Morocco.
Département de Génétique Médicale, Institut National d'Hygiène, 27 Avenue Ibn Batouta, B.P 769, 11400, Rabat, Morocco.
Breast Cancer Res Treat. 2022 Jul;194(1):187-198. doi: 10.1007/s10549-022-06622-3. Epub 2022 May 17.
Breast cancer (BC) is the most common form of female cancer around the world. BC is mostly sporadic, and rarely hereditary. These hereditary forms are mostly BRCA1- and BRCA2-associated hereditary breast and ovarian cancer syndrome. BRCA1 and BRCA2 genes are large and had some recurrent mutations specific to some populations. Through this work we analyze the most recurrent mutations in Moroccan population and compared them to a large review of other BRCA1/2 spectrum mutations in the MENA region.
We report in this work a series of 163 unrelated patients (the largest series of Moroccan patients) with familial breast and/or ovarian cancer, selected among patients referred to our oncogenetic outpatient clinic, from 2006 to 2021. To identify genetic variants in these two genes, different genetic analysis strategies have been carried out, using Sanger Sequencing DNA or Target Panel Sequencing.
Pathogenic variants were identified in 27.6% of patients. The most frequent mutation identified in our patients was the c.1310_1313delAAGA, BRCA2 (33%), and three other mutations seem more frequent in the Moroccan population (33%) of all reported patients: c.798_799delTT, BRCA1; and c.3279delC, BRCA1; and c.7234_7235insG in BRCA2 gene.
Through this work, we emphasize the importance of screening for BRCA1 and BRCA2 recurrent mutations in Moroccan patients. Other MENA (MENA: English-language acronym referring to the Middle East and North Africa region) countries had also some recurrent BRCA mutations, which will allow a fast and unexpensive first line genetic analysis and a precise molecular diagnosis. This will allow an adapted follow-up of the patients and a pre-symptomatic diagnosis of their relatives.
乳腺癌(BC)是全球女性最常见的癌症形式。BC 大多为散发性,很少为遗传性。这些遗传性形式大多与 BRCA1-和 BRCA2 相关的遗传性乳腺和卵巢癌综合征有关。BRCA1 和 BRCA2 基因较大,在某些人群中存在一些特定的高频突变。通过这项工作,我们分析了摩洛哥人群中最常见的突变,并将其与 MENA 地区其他 BRCA1/2 谱突变的大型综述进行了比较。
我们在这项工作中报告了 163 例无关的家族性乳腺癌和/或卵巢癌患者(摩洛哥患者中最大的系列),这些患者是从 2006 年至 2021 年在我们的肿瘤遗传门诊就诊的患者中选择的。为了在这两个基因中识别遗传变异,我们使用 Sanger 测序 DNA 或靶向 panel 测序进行了不同的遗传分析策略。
在 27.6%的患者中发现了致病性变异。在我们的患者中最常见的突变是 BRCA2 的 c.1310_1313delAAGA(33%),还有另外三个突变在摩洛哥人群中似乎更为常见(占所有报告患者的 33%):BRCA1 的 c.798_799delTT;BRCA1 的 c.3279delC;BRCA2 基因的 c.7234_7235insG。
通过这项工作,我们强调了在摩洛哥患者中筛查 BRCA1 和 BRCA2 高频突变的重要性。其他 MENA(MENA:中东和北非地区的英语首字母缩写)国家也有一些高频 BRCA 突变,这将允许快速、经济实惠的一线遗传分析和精确的分子诊断。这将允许对患者进行适当的随访,并对其亲属进行症状前诊断。